预约演示

Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

2023-10-18

交易

Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree

15.7 million U.S. children, teens and adults estimated to have been diagnosed with ADHD1,2

Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3

Glazer, who has always been outspoken about his mental health struggles, wants others to know that when it comes to ADHD, there are many going through similar experiences. By gaining a clear understanding of what ADHD is, common symptoms and how it affects people’s day to day lives, individuals can work with their doctors to choose the best course of action to suit their personal needs.

“I’m partnering with Supernus to help others overcome the stigmas associated with ADHD and help those diagnosed understand they are not alone,” says Glazer. “I’ve struggled a lot in my treatment journey. Since I was diagnosed later in life as an adult, it has been difficult trying to find the right treatment. Qelbree has helped me manage my ADHD symptoms, and I have Supernus to thank for that.”

October is ADHD Awareness Month, an important time to bring attention to the often complicated diagnosis and treatment journey and an opportunity for individuals to learn, educate and empower one another

“Supernus stands with the ADHD community year-round, and especially during ADHD Awareness Month, offering solidarity, support and understanding for those living with the condition,” says Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “We’re thrilled to see the impact that Qelbree has had on people living with ADHD, including Jay Glazer, and appreciate his willingness to join us during this important time of year and open up about his ADHD story of perseverance and optimism.”

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.

1Centers for Disease Control and Prevention. Data and Statistics About ADHD. Centers for Disease Control and Prevention. https://www.cdc.gov/ncbddd/adhd/data.html.

2Castellanos, F. X. (2012). Large-Scale Brain Systems in ADHD: Beyond the Prefrontal-Striatal Model. Trends in Cognitive Science. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272832/.

3Culpepper, L., Mattingly, G. (2010). Challenges in Identifying and Managing Attention-Deficit/Hyperactivity Disorder in Adults in the Primary Care Setting: A Review of the Literature. Primary Care Companion Journal of Clinical Psychiatry.

The content above comes from the network. if any infringement, please contact us to modify.

机构

适应症